• Explore /
  • Poster
  • / Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.

Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.

Abstract Video & Slides Poster

Authors

null

Ryan C Lynch

University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA

Ryan C Lynch , Pamela N. Munster , Ranjana H. Advani , Mehdi Hamadani , David R. Spigel , Gerald Steven Falchook , Manish R. Patel , David Samuel DiCapua Siegel , Nina Beri , Grzegorz S. Nowakowski , Neil Palmisiano , Monika Leigh Burness , Kathleen N. Moore , Geoffrey Shapiro , Dejan Juric , William D. Bradley , Thomas J. O'Shea , Markus Frederic Renschler , Judson M. Englert , Timothy A. Yap

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT03997968

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3084)

DOI

10.1200/JCO.2022.40.16_suppl.3084

Abstract #

3084

Poster Bd #

76

Abstract Disclosures

Similar Posters

First Author: Victor Moreno

First Author: Paul Hamberg

First Author: Neil Howard Segal

First Author: Funda Meric-Bernstam